Cross-organ hierarchy of HLA molecular mismatches in donor-specific antibody development in solid organ transplantations.

Journal: Cell reports. Medicine
Published Date:

Abstract

Donor-specific antibodies (DSAs) against human leukocyte antigen (HLA) play a crucial role in antibody-mediated rejection, a major barrier to successful organ transplantation. Donor-recipient HLA molecular incompatibility critically influences DSA susceptibility, commonly assessed by analyzing mismatches in the HLA eplet repertoire. This study, including six distinct liver, lung, and kidney transplant cohorts from two centers (978 donor-recipient pairs), explores associations between individual eplet mismatches and DSA development. Certain mismatched eplets are strongly linked to DSA development, while others show weaker associations, a trend consistent across different organ types. Machine learning leverages these hierarchical associations to develop an eplet risk score (ERS), outperforming traditional eplet mismatch assessments. Furthermore, T cell proliferation in mixed lymphocyte reaction in vitro correlates with the ERS, attenuated by antibody-mediated inhibition of a mismatched DSA-associated eplet. These results establish the differential immunological impacts of mismatched HLA eplets as integral in clinical practice and therapeutic innovation.

Authors

  • Masaaki Hirata
    Department of Surgery, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501, Japan.
  • Kazuto Tsukita
    Department of Neurology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501, Japan; Advanced Comprehensive Research Organization, Teikyo University, Itabashi-ku, Tokyo 173-8605, Japan; Division of Sleep Medicine, Kansai Electric Power Medical Research Institute, Fukushima-ku, Osaka 553-0003, Japan.
  • Takero Shindo
    Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501, Japan; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan. Electronic address: takeros@kuhp.kyoto-u.ac.jp.
  • Shintaro Yagi
    Department of Surgery, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501, Japan; Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kanazawa University, Kanazawa 920-8640, Japan.
  • Takashi Ito
    Department of Surgery, Graduate School of Medicine Kyoto University Kyoto Japan.
  • Satona Tanaka
    Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501, Japan.
  • Ryo Fujimoto
    Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501, Japan.
  • Hidenao Kayawake
    Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501, Japan.
  • Kenji Nakamura
  • Nobuhiro Fujiyama
    Center for Kidney Disease and Transplantation, Akita University Hospital, Akita 010-0041, Japan.
  • Mitsuru Saito
    Department of Urology, Akita University School of Medicine, Akita.
  • Kimiko Yurugi
    Department of Clinical Laboratory, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan.
  • Rie Hishida
    Department of Clinical Laboratory, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan.
  • Arisa Kato
    Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501, Japan.
  • Atsushi Kawaguchi
    Section of Clinical Cooperation System, Center for Comprehensive Community Medicine, Faculty of Medicine, Saga University, Saga, Japan.
  • Tomonori Habuchi
    Department of Urology, Akita University School of Medicine, Akita.
  • Takashi Kobayashi
  • Hiroshi Date
    Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan. Electronic address: hdate@kuhp.kyoto-u.ac.jp.
  • Etsuro Hatano
    Department of Surgery, Graduate School of Medicine Kyoto University Kyoto Japan.